Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CD38 | P28907 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178751 | 0.86 | KMT2A (0.46) | KMT2AP2RX7 | |
| SCHEMBL1178940 | 0.81 | POLB (0.39) | NPC1POLBMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL1178134 | 0.81 | MAPT (0.48) | KMT2ACD38P2RX7POLBMAPT | |
| SCHEMBL1180626 | 0.81 | POLB (0.39) | KMT2ANPC1POLBMAPTSMN1; SMN2 | |
| SCHEMBL561197 | 0.74 | LMNA (0.53) | CD38P2RX7SMN1; SMN2 | |
| SCHEMBL4209923 | 0.72 | LMNA (0.46) | KMT2AP2RX7NPC1POLBMAPT | |
| SCHEMBL1178846 | 0.72 | ATM (0.49) | KMT2AP2RX7POLBMAPTSMN1; SMN2 | |
| SCHEMBL11348223 | 0.72 | MAPK1 (0.58) | KMT2APOLBMAPTSMN1; SMN2MEN1 | |
| SCHEMBL11349161 | 0.72 | APP (0.45) | P2RX7NPC1MAPK1 | |
| SCHEMBL1178125 | 0.72 | POLB (0.46) | KMT2ANPC1POLBSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459542-B1 | Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists | ALLERGAN INC (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2459542-B1 | Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists | ALLERGAN INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8329918-B2 | Selective alpha 2B/2C agonists | ALLERGAN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329918-B2 | Selective alpha 2B/2C agonists | ALLERGAN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329918-B2 | Selective alpha 2B/2C agonists | ALLERGAN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2459542-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | Allergan, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2011014332-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | ALLERGAN, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014332-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | ALLERGAN, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ADRA2C, ADRA2B, ADRB2 | KMT2A 4074/4885CD38 1384/4885P2RX7 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.